BioMarin Pharmaceutical (MEX:BMRN) Retained Earnings: MXN4,684 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
21 GF Score
Price MXN959.00
GF Value MXN1,514.04
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Retained Earnings?

BioMarin Pharmaceutical MEX:BMRN 21 Retained Earnings is MXN4,684 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 21/100 and a GF Value™ of MXN1,514.04 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BioMarin Pharmaceutical's retained earnings for the quarter that ended in Mar. 2026 was MXN4,684 Mil.

BioMarin Pharmaceutical's quarterly retained earnings declined from Sep. 2025 (MXN3,683 Mil) to Dec. 2025 (MXN2,777 Mil) but then increased from Dec. 2025 (MXN2,777 Mil) to Mar. 2026 (MXN4,684 Mil).

BioMarin Pharmaceutical's annual retained earnings increased from Dec. 2023 (MXN-10,550 Mil) to Dec. 2024 (MXN-4,061 Mil) and increased from Dec. 2024 (MXN-4,061 Mil) to Dec. 2025 (MXN2,777 Mil).


BioMarin Pharmaceutical  (MEX:BMRN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


BioMarin Pharmaceutical Retained Earnings Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Retained Earnings Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19,093.61 -15,386.22 -10,550.41 -4,060.50 2,776.59

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -184.31 4,359.39 3,683.13 2,776.59 4,683.69
MEX:BMRN
21GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN4,684 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Retained Earnings of MXN4,684 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Retained Earnings too high?
BioMarin Pharmaceutical's current Retained Earnings is MXN4,684 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 21/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Retained Earnings compare to TECH and CYTK?
BioMarin Pharmaceutical's Retained Earnings of MXN4,684 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Retained Earnings is MXN4,684 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,514.04, compared to a current price of MXN959.00 — trading 36.7% below its estimated fair value. The current Retained Earnings is MXN4,684 Mil. BioMarin Pharmaceutical's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Retained Earnings is MXN4,684 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 36.7% below its estimated GF Value™ of MXN1,514.04. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Retained Earnings: MXN4,684 Mil
  • GF Value™: MXN1,514.04 vs. price of MXN959.00 (36.7% below fair value)
  • GF Score™: 21/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
21GF Score

Get the complete analysis for MEX:BMRN

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,514.04
GF Value